Chugai Pharmaceutical manufactures, sells, imports and exports pharmaceuticals and has become the leading biopharmaceutical company in Japan.
Founded in Tokyo back in 1925 Chugai Pharmaceutical is a member of the Roche Group and has subsidiaries all around the world. The company focuses on many different therapeutic areas that range from oncology to bone/joint diseases and renal diseases. Just recently the company has announced that it will start to venture into the unmet medical world of CNS diseases. It will also continue its work into creating the next generation of antibody technologies to develop drugs and explore personalized medicine as a means of delivery targeted medications.
After the company was founded in 1925 it officially established in 1943 and started listing stock on the stock exchange in the 1950’s. Following a large period of growth Chugai acquired the USA based company Gen-Probe in 1989 and launched the product Epogin®, a recombinant human erythropoietin the following year. In the next decade the company expanded itself significantly by converting its London office into the European subsidiary Chugai Pharma Europe Ltd, Setting up Chugai Biopharmaceuticals (now Chugai Pharma USA) and Chugai Diagnostics. Then in 2002, a major development in the company’s history occurred as it merged with Nippon Roche K.K. who had just successfully launched the breast cancer drug Herceptin.
From here on in Chugai changed as it had so many more opportunities available to it both in terms of development and network connections. Chugai could now sell its products through Roche’s sales teams and locations, its reputation also benefitted from the general affiliation with the Swiss company.
Partnering for products
In addition to developing its own products Chugai Pharmaceutical licenses in many of its products through agreements with big pharmaceutical and biotech companies such as Genentech and Sanofi. The products that are licensed in are often developed in the European arm of the company known as Chugai Pharmaceutical Europe. Products are developed from pre-clinical to phase III.
Chugai has many partnerships in place with pharmaceutical companies worldwide; many are signed at the early development stages showing Chugai’s preference for developing many products itself through to approval and marketing. Companies who have signed partnership agreements include Antitope, Taisho Pharmaceutical, Sanofi, Vegenics, Kowa and Helsinn Healthcare.
Chugai Pharmaceutical is often present at a large number of partnering events throughout the year. Partnering events are a great place to meet lots of potential partners face to face in a short space of time.
Other events with Chugai Pharmaceutical’s presence include but are not limited to:
- BIO International Convention and Business Forum
- BioEurope / BioEurope Spring
For a full list of forthcoming partnering events where you could meet with Chugai Pharmaceutical in person visit Current Partnering’s Event calendar.
Contacting Chugai Pharmaceutical for partnering
Chugai Pharmaceutical can be contacted in relation to partnering through a number of channels. Here is a list of the most common channels:
Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.
See Current Partnering’s event calendar for details of forthcoming events.
Direct contact: there are several sources of direct contact with Chugai Pharmaceutical’s business development team
- Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.
- Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. This page on the Chugai Pharmaceutical’s website has details for contacting Chugai Pharmaceutical.
- LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel.
Many of Chugai Pharmaceuticalbusiness development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit Chugai Pharmaceutical Linkedin Page.
Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above. This is the contacts page on Chugai Pharmaceutical website for potential partnering opportunities and general contact names.
Our report provides more detailed insight into the details of each deal. See: Partnering Agreements with Chugai Pharmaceutical 2009-2014
Chugai Pharmaceutical partnering at Current Agreements
Full details on each deal can be found at Current Agreements (subscription required)
Or purchase report: Partnering Agreements with Chugai Pharmaceutical 2009-2014
No M&A activity for Chugai Pharmaceutical
Available reports from Current Partnering
Report: Partnering Agreements with Chugai Pharmaceutical 2009-2014
Available resources for deal coverage for Chugai Pharmaceutical
Read: more on Chugai Pharmaceutical company profile, recent partnering, M&A and financing news and articles
Report: Finding Biopharma Licensing and Collaboration Partners
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk